Dawnrays Pharma was founded in December 1995, it is principally engaged in the development, manufacture and sales of cephalosporin antibiotics and system specific medicines. Dawnrays Pharmaceutical (Holdings) Limited was listed on the main board of The Hong Kong Stock Exchange on July 11, 2003 with stock code 02348.HK.

Dawnrays Pharma owns nine subsidiaries, namely Dawnrays International Company Limited, Dawnrays International Co., Ltd., Dawnrays Biotechnology Capital (Asia) Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Dawnrays Pharma (Hong Kong) Limited, Fujian Dawnrays Pharmaceutical Co., Ltd., Lanzhou Dawnrays Pharmaceutical Co., Ltd. and Suzhou Dawnrays Pharmaceuticals Trading Co., Ltd. As a Hong Kong listed company, the Group’s overall decision-making and management strictly conform to Hong Kong corporate governance requirements, its business positioning is fixed on a global perspective while holding angles on the entire globe and inclusion of world culture and hence we are a trustworthy enterprise for investors.

The products of cephalosporin antibiotics cover intermediates, bulk medicines and powder for injections. The system specific medicines cover therapeutic areas for cardiovascular system, anti-HBV, anti-allergic, digestive system, urinary system, endocrine system with dosage forms of tablets, capsules and granules. For the production of cephalosporin antibiotics, Dawnrays Pharma adopts a distinctive comprehensive vertically integrated process from pharmaceutical intermediates to bulk medicines and finished drugs. In particular in the area of chemical synthesis for the 3rd generation cephalosporin, it is equipped with advanced technology platform, the quality of products has reached international advanced level, which has established an industrial chain of cephalosporin with extensive product portfolio, perfect comprehensive coordinated function, potentially high production capacity, hence we are the first chosen raw material supplier for domestic major pharmaceutical manufacturers and many overseas pharmaceutical manufacturers.

Dawnrays Pharma's R & D center was founded in 2002, includes nearly 50 core research fellows, is a R & D team taking professionals as core members and consisting of senior researchers such as doctors and masters degrees holders. The R & D direction mainly focuses on generic drugs of system specific medicines, while taking into consideration the researching and developing of new classes of drugs and exploration of some innovative drugs. Every year, R & D input accounts for about 10% of turnover of the Group's system specific medicines. At present, Dawnrays Pharma has established a series of cardiovascular drugs' brand equity represented by “An”, while specific medicines viz. “Amlozen™”, “An Neixi”, “Cecoride™”, “Rallyado™” are all among the first batch of generics in China that received approval for launching into the market and their market shares have been ranked high.

Dawnrays Pharma has set up 4 sales teams according to different product lines, covering several models such as hospital, distribution, bulk medicines and import & export, respectively. As of late, there are approximately 550 people in the sales team spread across and in excess of 90 cities. In which 40% are located in the first-tier cities, 30% in the second-tier cities, therefore, Dawnrays Pharma has good capacity for distributing new products to hospitals rapidly.

Dawnrays Pharma boasts a sound quality management system, while its existing plants are constructed strictly according to EU standards. Dawnrays Pharma has been devoting itself to the health of human beings. With the high sense of social responsibility, forward-looking thought and the continuous effort in technological innovations, Dawnrays Pharma will keep delivering safe and effective drugs to the society, contributing itself to the health of human beings, constructing a first-class pharmaceutical enterprise in China for investors.

苏公网安备 32050602010200号